Value
9.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 9.0 |
- ▸Attractively valued
AMLX · Why this verdict
Why Amylyx Pharmaceuticals (AMLX) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.2/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Amylyx is a cash-burning, pre-revenue biotech with a quality score of 1.6/10 and a single-asset pipeline, offset by 28.5% upside to the analyst target and constructive price momentum ahead of earnings in 4 days.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The pipeline is concentrated in avexitide and supply depends on third-party contract manufacturers, so a single clinical or supply setback would hit the whole thesis. Bear case | Pipeline progress on avexitide should continue without manufacturing disruption. | ↓Deteriorating |
| CounterConcentration is also the source of the upside, and a positive trial readout could re-rate the stock sharply. | ||
Amylyx is cash-burning with negative free cash flow and no competitive moat, giving it a quality score of just 1.6/10, below the 4.0 minimum for a holding. Quality breakdown | Cash burn should be funded without dilution and quality metrics should improve as the pipeline matures. | →Stable |
| CounterPre-revenue biotechs are structurally cash-burning, and the balance sheet looks conservative (debt-to-equity component 9.9/10), so low quality may not signal distress. | ||
The price of $28.86 sits 28.5% below the $37.09 analyst target, with 9.8% downside and a reward-to-risk of 2.92, and analyst rating scores 8.3/10. Upside pct | Price should move toward the $37.09 target without breaching the $26.84 stop level. | →Stable |
| CounterAnalyst targets for pre-revenue biotechs are speculative, and the earnings record is mixed (2 beats and 2 misses). | ||
Insiders sold about $3.78 million across 11 sales in 90 days with no purchases, a bearish signal equal to 0.104% of market cap. Net value 90d | Insider selling should taper off and stay immaterial relative to market cap. | →Stable |
| CounterSales may be pre-scheduled or tax-related and not reflect views on the pipeline. | ||
Momentum is constructive at 6.8/10, with the stock above its 200-day average and rising on-balance volume. Momentum breakdown | Price should hold above the 200-day average through the November 5 earnings report. | ↑Improving |
| CounterVolume component is weak at 1.7/10 and technical score is only 2.8/10, so the rally lacks broad confirmation. | ||
The pipeline is concentrated in avexitide and supply depends on third-party contract manufacturers, so a single clinical or supply setback would hit the whole thesis.
↓DeterioratingBear case
- Expectation
- Pipeline progress on avexitide should continue without manufacturing disruption.
CounterConcentration is also the source of the upside, and a positive trial readout could re-rate the stock sharply.
Amylyx is cash-burning with negative free cash flow and no competitive moat, giving it a quality score of just 1.6/10, below the 4.0 minimum for a holding.
→StableQuality breakdown
- Expectation
- Cash burn should be funded without dilution and quality metrics should improve as the pipeline matures.
CounterPre-revenue biotechs are structurally cash-burning, and the balance sheet looks conservative (debt-to-equity component 9.9/10), so low quality may not signal distress.
The price of $28.86 sits 28.5% below the $37.09 analyst target, with 9.8% downside and a reward-to-risk of 2.92, and analyst rating scores 8.3/10.
→StableUpside pct
- Expectation
- Price should move toward the $37.09 target without breaching the $26.84 stop level.
CounterAnalyst targets for pre-revenue biotechs are speculative, and the earnings record is mixed (2 beats and 2 misses).
Insiders sold about $3.78 million across 11 sales in 90 days with no purchases, a bearish signal equal to 0.104% of market cap.
→StableNet value 90d
- Expectation
- Insider selling should taper off and stay immaterial relative to market cap.
CounterSales may be pre-scheduled or tax-related and not reflect views on the pipeline.
Momentum is constructive at 6.8/10, with the stock above its 200-day average and rising on-balance volume.
↑ImprovingMomentum breakdown
- Expectation
- Price should hold above the 200-day average through the November 5 earnings report.
CounterVolume component is weak at 1.7/10 and technical score is only 2.8/10, so the rally lacks broad confirmation.
Per-dimension breakdown
Quality
1.6/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 4.8 |
| Piotroski F | 4.4 |
- ▸Cash-burning (FCF negative)
- ▸No competitive moat
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
7.5/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.5 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 7.0 |
| Volume | 4.8 |
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
7.6/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 5.3 |
| Analyst rating | 8.3 |
| Price target | 9.4 |
- ▸Analyst upside: 45%
Insider
3.3/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 3.0 |
| insider conviction | 2.0 |
| holder change | 5.0 |
- ▸Notable insider selling — $3,775,866 (0.103% of mkt cap)
Peer rank
4.8/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 0.0 |
| growth rank | 5.0 |
- ▸Conservative debt levels
Technical
3.0/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.9 |
| support resistance | 2.8 |
| 52w position | 4.3 |
| gap | 4.0 |
Risk (lower is worse)
2.5/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 3.4 |
| days to cover | 0.6 |
| volatility | 0.0 |
| put call | 1.2 |
| implied vol | 0.0 |
| debt equity | 9.9 |
- ▸Elevated put/call: 1.82
- ▸High IV: 83%
- ▸Concentration risks: 2 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
4.8/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 3.3 |
| earnings timing | 5.0 |
| surprise avg | 3.6 |
| news activity | 7.0 |
- ▸Earnings concerns: 2B/2M
- ▸Earnings today
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCK:QUALITY_FLOORPassed (7)
- MOMENTUM:7.5>=5.5
- ASYMMETRY:2.3>=1.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- EARNINGS_PROXIMITY:0d<=7d
Warning (0)
none
Reward-to-Risk
2.29
Upside
+26.2%
Downside
11.4%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeNo clear edge — No clear edge identified
SuitabilityAggressive — MCap $3.7B<$5B
Investment implication
The SELL_IF_HOLDING verdict reflects the EARNINGS_PROXIMITY gate's 0d<=7d outcome against Value at 9.0 and asymmetric R:R of 2.29.
The strongest dimensions are Value at 9.0, Sentiment at 7.6, and Momentum at 7.5; the weakest are Quality at 1.6, Risk (lower is worse) at 2.5, and Technical at 3.0. The V9 engine flagged 1 failed gate, producing an asymmetric reward-to-risk of 2.29 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Cash Burning Low Quality
Trip ifQuality score rises above 4.0 from the current 1.6.
- P2Single Asset Pipeline Concentration
Trip ifNumber of clinical-stage assets beyond avexitide rises to at least 2.
- P3Analyst Target Upside
Trip ifAnalyst target falls below $31, less than 8% above the current $28.86 price.
- P4Insider Selling Pressure
Trip ifNet insider selling exceeds $8 million over 90 days from the current $3.78 million.
- P5Constructive Price Momentum
Trip ifMomentum score falls below 4.5 from the current 6.8.